Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Ductal Carcinoma In Situ with Diffuse Growth Distribution: A Potentially Lethal Subtype of “Preinvasive” Disease

Thomas J O’Keefe, Olivier Harismendy, Anne M Wallace
doi: https://doi.org/10.1101/2020.09.17.20196931
Thomas J O’Keefe
1Division of Breast Surgery And The Comprehensive Breast Health Center, University of California San Diego Mailbox 0819, 3855 Health Sciences Dr, La Jolla, CA 92037
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tokeefe@health.ucsd.edu
Olivier Harismendy
2Moores Cancer Center and Division of Biomedical Informatics, Department of Medicine, University of California San Diego 3855 Health Sciences Dr, La Jolla, CA 92037
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne M Wallace
1Division of Breast Surgery And The Comprehensive Breast Health Center, University of California San Diego Mailbox 0819, 3855 Health Sciences Dr, La Jolla, CA 92037
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

PURPOSE The current trend in ductal carcinoma in situ (DCIS) research is towards treatment de-escalation. Problematically, prognostic indicators for patients at high risk of breast cancer mortality (BCM), rather than recurrence, have not been identified. We aim to identify prognostic factors for the development of metastatic disease and mortality.

EXPERIMENTAL DESIGN Patients diagnosed with DCIS in a local cancer registry as well as in the National Cancer Database (NCDB) and the Surveillance, Epidemiology and End Results (SEER) program were assessed for factors prognostic of metastatic disease, overall, and breast-cancer specific survival. Cox and competing risks regressions were developed.

RESULTS Among 5 patients who developed distant metastatic disease in the cancer registry, 3 had identifiable growth distribution; all 3 were diffuse type. None had in-breast invasive or DCIS recurrences before metastasis. In NCDB and SEER, cumulative incidence of any cause mortality (ACM) and BCM at 10 years was 12%/5.0% for diffuse lesions; 8%/3.6% for patients with microinvasive disease, 7.4%/2.3% for lesions >5 cm, 5.6%/1.4% for lesions 2-5 cm and 5.5%/1.5% for lesions <2 cm. Multivariate hazard ratios for ACM in NCDB and BCM in SEER were 2.0 and 5.3 (p=0.03 and 0.02, respectively). Among patients with diffuse lesions, cumulative incidence ACM at 10 years was 15.0% among those undergoing unilateral mastectomy vs. 2.5% among those undergoing bilateral mastectomy (p=0.11).

CONCLUSION Diffuse DCIS represents an uncommon but deadly subtype for whom treatment escalation, rather than de-escalation, is likely necessary. Further studies elucidating the mechanism of metastasis and best treatment course are needed.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The author Olivier Harismendy is supported by grants for other work but none of the authors received funding regarding work presented in this manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

UCSD Human Research Protections Program approved the IRB for the single-institution portion of the study and waived the need for approval for the SEER and NCDB studies as it involved publicly available, deidentified data.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Research support: Olivier Harismendy is supported by awards from the National Cancer Institute (U01CA196406 and P30CA023100)

  • Prior presentations: This study has not been previously presented

  • Disclaimers: None of the authors have any relevant conflicts of interest to disclose

Data Availability

SEER and NCDB data are maintained by NIH and American College of Surgeons, respectively. Data in the single institution analysis are not publicly available as they contain PHI but the records are obtainable for research parties with IRB approval through the UCSD HRPP.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted September 18, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Ductal Carcinoma In Situ with Diffuse Growth Distribution: A Potentially Lethal Subtype of “Preinvasive” Disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Ductal Carcinoma In Situ with Diffuse Growth Distribution: A Potentially Lethal Subtype of “Preinvasive” Disease
Thomas J O’Keefe, Olivier Harismendy, Anne M Wallace
medRxiv 2020.09.17.20196931; doi: https://doi.org/10.1101/2020.09.17.20196931
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Ductal Carcinoma In Situ with Diffuse Growth Distribution: A Potentially Lethal Subtype of “Preinvasive” Disease
Thomas J O’Keefe, Olivier Harismendy, Anne M Wallace
medRxiv 2020.09.17.20196931; doi: https://doi.org/10.1101/2020.09.17.20196931

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (214)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1091)
  • Dentistry and Oral Medicine (194)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (497)
  • Epidemiology (9747)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2299)
  • Geriatric Medicine (221)
  • Health Economics (461)
  • Health Informatics (1548)
  • Health Policy (729)
  • Health Systems and Quality Improvement (600)
  • Hematology (236)
  • HIV/AIDS (500)
  • Infectious Diseases (except HIV/AIDS) (11623)
  • Intensive Care and Critical Care Medicine (615)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2137)
  • Nursing (133)
  • Nutrition (332)
  • Obstetrics and Gynecology (424)
  • Occupational and Environmental Health (516)
  • Oncology (1171)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (308)
  • Pediatrics (693)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2168)
  • Public and Global Health (4640)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (451)
  • Respiratory Medicine (622)
  • Rheumatology (273)
  • Sexual and Reproductive Health (224)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (42)
  • Transplantation (120)
  • Urology (94)